Zoetis, Neogen deal draws antitrust concerns in Australia

Australia's competition regulator is scrutinising Zoetis' acquisition of Neogen on antitrust grounds, potentially blocking or conditioning a deal in the animal health market. The challenge signals tightening M&A review in agribusiness across Asia-Pacific jurisdictions. If you're building or selling animal health diagnostics, genetics, or feed additives in Australia or Asia-Pacific, the window for acquisition by a tier-one player just narrowed. Zoetis faced antitrust resistance even with Neogen at scale - smaller deals may now face similar scrutiny or longer review cycles that kill valuations.